Berlin, Germany, and Research Triangle Park, NC, USA, April 18, 2024 (GLOBE NEWSWIRE) — Not intended for UK Media AB-1002 is being studied for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms AskBio is currently enrolling patients in the Phase […]
Coronary/Structural Heart
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
MONTREAL and CHARLOTTE, N.C., April 17, 2024 (GLOBE NEWSWIRE) — Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at the 30th Annual Cardiovascular Nursing Symposium held by the Preventive Cardiovascular Nurses Association on April 18-20th in Orlando, FL. The posters will be available following the embargo at https://MilestonePharma.com.
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Diego on May 17-22, 2024. At ATS, United Therapeutics will […]
Acticor Biotech will Present the Clinical Results of Its Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024
PARIS–(BUSINESS WIRE)–Regulatory News: “ACTISAVE Clinical Trial: Efficacy and Satefy of Glenzocimab on Top of Thrombolysis with or without Mechanical Thrombectomy” Post this ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, focusing stroke, announces today its participation […]
TRIA™ Polymer Surgical Valves Surpass 200 Patient Life Years
SALT LAKE CITY–(BUSINESS WIRE)–Foldax®, Inc., a leader in the development of innovative, polymer heart valves, today announced that its TRIA valves have surpassed 200 patient life years in human recipients. Patient life years represent the cumulative time the valve has been implanted in patients, offering insight into the duration of […]
Caranx Medical announces successful world first robotic assisted transcatheter heart valve implantation in an animal
NICE, France–(BUSINESS WIRE)–Caranx Medical (‘Caranx’), a French medical device company specializing in the development of autonomous robot to democratize access to Transcatheter Aortic Valve Implantation (TAVI), a lifesaving procedure, today announced the successful world first robotic assisted heart valve (aortic valve) implantation in an animal. The assisted heart valve implantation […]
Annoviant™ Awarded $2.99 Million NIH Grant to Advance TxGuard™ Pulmonary-Valved Conduit for Pediatric Heart Disease
ATLANTA, April 16, 2024 /PRNewswire/ — Annoviant™, Inc., a pioneering company with a breakthrough TxGuard™ technology platform for soft-tissue healing, currently focused on cardiovascular field, proudly announces receipt of a $2.99 million grant (SBIR Phase 2b) from the National…
CVRx announces availability of additional data supporting long-term benefits of Barostim
MINNEAPOLIS, Minn., April 15, 2024 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today the availability of additional data, including the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of Heart Failure. These data highlight long-term sustained benefits […]
DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)
The Premier Event for Cardiovascular Industry Leaders and Clinicians
Breakthrough Cardiac Study Reveals Long-Term Impact on Post-Transplant Survival: A 2-Year Clinical Investigation Advancing Heart Preservation
WALTHAM, Mass.–(BUSINESS WIRE)–Paragonix Technologies, Inc., a pioneer in organ transplant technologies and services, announces the annual release of the latest GUARDIAN-Heart Clinical Registry report, shared earlier today at the 44th ISHLT Annual Meeting and Scientific Sessions – one of the largest international conferences focused on advanced treatment for end-stage heart […]



